Sanofi’s vaccine sales have dropped by 4.8% in the second quarter of 2024, reportedly due to a decrease in COVID-19 vaccine sales compared to last year. The company’s overall financial performance remains strong though, driven by Dupixent and other new medicines. Sanofi reported a 10.2% increase in net sales for the quarter, despite challenges in the vaccine sector.